WolverHeme Happy Hour

By Bernard Marini, Anthony Perissinotti, et al.

What's WolverHeme Happy Hour about?

Welcome to WolverHeme Happy Hour! This is a podcast dedicated to all things hematology! We discuss new data, debate controversial therapies, and talk about new and exciting research. While we nerd out about data, we'll have a few drinks!

Disclaimer: The views and opinions expressed on this podcast are solely those of the podcasters and guests and do not reflect the views or opinions of our employers or other affiliations.

Download our free app to listen on your phone

WolverHeme Happy Hour episodes:

06.13.2024
From Ancient Remedies to Modern Miracles: The Evolution of APL Treatment
In this episode, Bernie and Anthony review the full history of APL treatment, in preparation for the upcoming plenary presentation of the APOLLO study THIS WEEKEND at EHA 2024! How did we get to our current standard of care in...
04.17.2024
Episode 24: Myeloma Madness with the Myeloma Man
In this episode, Anthony and Bernie are joined by Multiple Myeloma expert Dr. Manni Mohyuddin, to discuss the recent FDA approval updates of CAR-T in this disease state. We also discuss the hotly debated topic of MRD as a surrogate...
01.25.2024
Anthony and Bernie get rich on no-larabine! An ASH 2023 ALL discussion
In this episode, Anthony and Bernie review the most impactful and interesting ALL abstracts at the 2023 ASH Annual Meeting. We dive into the nelarabine abstracts, calaspargase (cal-peg), and the evolution of the treatment of Ph+ ALL! Abstracts discussed: https://ash.confex.com/ash/2023/webprogram/Paper190141.html -...
12.29.2023
LymphOMG: Pouring Over Lymphoma Abstracts from ASH
OMG! In this extra fun holiday episode, we are joined by lymphoma experts Tycel Phillips and Aaron Goodman to review the most impactful and controversial lymphoma abstracts from ASH! Stay tuned for a lively discussion! Abstracts Discussed! SYMPATICO (Ibrutinib +...
12.19.2023
AMLchemy at ASH: Brewing Success with Menin Magic, MRD Mysteries, and Aza/Ven Alchemy
In this episode, Anthony and Bernie discuss the AML abstracts at ASH that we found most intriguing and controversial! Abstracts: FILO - Stopping Aza/Ven: https://ash.confex.com/ash/2023/webprogram/Paper185437.html Revumenib Late Breaking Abstract: https://ash.confex.com/ash/2023/webprogram/Paper192042.html JNJ617 Menin Inhibitor Data: https://ash.confex.com/ash/2023/webprogram/Paper172422.html SAVE Trial (Revumenib +...
12.01.2023
ASH Pregaming - Myeloma Madness with Manni and Papa Heme
In this episode, Anthony and Bernie are joined by two very special guests - Dr. Aaron "Papa Heme" Goodman and Dr. Manni "Myeloma Man" Mohyuddin - to discuss the most interesting myeloma abstracts at the upcoming 2023 ASH meeting! Will...
11.08.2023
AML Maintenance Part 2: a metaMORPHOsis?
In the second portion of our two part-series on AML maintenance, Anthony and Bernie delve into the studies of post-transplant FLT3 inhibitor maintenance. We discuss the controversial MORPHO study of gilteritinib and whether these results will change practice! Sorafenib...
10.25.2023
AML Maintenance Part 1: Set Your QUAZARs to Stun
In the first of a two part-series, Anthony and Bernie dive into the data surrounding maintenance therapies in AML. This episode focuses on maintenance therapy for patients ineligible for transplant, with a focus on oral azacitidine and the controversial QUAZAR...
08.23.2023
Episode 17: The Hemophilia Eras Tour
In this episode, we are joined by classical hematology experts, Madeleine Ochs, PharmD, BCOP and Justin Arnall, PharmD, BCOP, to teach us hemophilia 101! In this T-Swift themed, episode, we discuss the history of hemophilia treatment (through the "eras") and...
08.01.2023
Common Sense Oncology: Outcomes That Matter
In this episode, Anthony and Bernie chat with Chris Booth, MD, and Aaron "Papa Heme" Goodman, MD, to talk about the Common Sense Oncology movement! Join the Common Sense Oncology movement at this link (it's free!): https://commonsenseoncology.org/ Lancet Oncol paper: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00319-4/fulltext
06.08.2023
All too well: the reality of leukemia treatment
In this episode, Anthony, Bernie, and Lydia are joined by a former patient, Madeline B, to talk about her ALL treatment journey. Drawing inspiration from Taylor Swift's upcoming concert and heartfelt ballad ("All Too Well"), this episode tackles some of...
05.09.2023
Episode 14: A Quantum Leap in AML Treatment? Dissecting Quizartinib Data with Dr. Dale Bixby
In this episode, Anthony and Bernie are joined once again by special guest and hematology expert, Dr. Dale Bixby, to discuss the recent publication of the QUANTUM-First study of quizartinib in newly diagnosed AML. Should this study change practice in...
02.24.2023
Episode 13: You get blinatumomab! You get blinatumomab!
Blinatumomab - it's Oprah's new favorite drug! On this episode, Anthony and Bernie are joined by special guests Dr. Lydia Benitez and Dr. Patrick Burke to discuss the ECOG1910 trial of blinatumomab in adult ALL. Is this trial practice changing? Listen...
02.08.2023
Episode 12: Tinder for T Cells - Bispecifics in DLBCL
In this episode, we are joined by two lymphoma experts - Victoria Nachar, PharmD, BCOP and Tycel Phillips MD - to discuss the use of bispecific antibodies in Diffuse Large B-Cell Lymphoma (DLBCL)! Stay tuned for an exciting episode where...
01.21.2023
Episode 11: "Olu the Drunk Snowman" - IDH inhibitors in R/R AML with Dr. Jill Lykon
In this episode, we are joined by Dr. Jill Lykon, Clinical Pharmacist Specialist in Hematology at the University of Miami, to discuss the use of IDH inhibitors in relapsed/refractory AML. How do we choose between IDH inhibitors? Is "Olu" the...
12.21.2022
Episode 10: ASH Recap Part 2 - Papa Heme + WolverHeme
In this episode, we are joined by the legendary hematologist and rock star - Dr. Aaron Goodman - aka "Papa Heme"! We discuss which ASH abstracts might be practice changing and which simply don't make the cut. Stay tuned for...
12.14.2022
Episode 9: ASH Recap Part 1 - Dauno-Double Trouble
In this episode, Anthony and Bernie begin to recap some interesting studies presented at ASH, starting with a discussion the results of the "Dauno-Double" Trial. Should it change practice? Dauno-Double Trial: https://ash.confex.com/ash/2022/webprogram/Paper157126.html Dr. Todd Lee breaking down the non-inferiority numbers: https://twitter.com/DrToddLee/status/1600662377250586627?s=20&t;=RdIhJJpMG-G_oPUSH2u2mw
11.23.2022
Episode 8: Pulling the Goalie on FLT3 Inhibitor Use in AML - A Discussion with Dr. Dale Bixby
In this enlightening episode, Anthony and Bernie chat about FLT3+ AML with Dr. Dale Bixby, Clinical Professor and expert in leukemia at the University of Michigan. We use two clinical cases to take a deep dive into the biology and...
10.07.2022
Episode (3+)7: Straight Outta Roswell - OG AML Data
Finally back from a much needed vacation, in this episode, Anthony and Bernie discuss some of the "OG" data and pharmacology behind key AML therapies.
07.21.2022
Episode 6: Dr. StrangeDrug or: How I Learned to Stop Worrying and Love the Asparaginase
In this episode, Bernie and Anthony do an in-depth dive into the pharmacology, toxicity management, and clinical conundrums with asparaginase therapy, including how and when to monitor asparaginase activity levels (per Papa Heme request!). For those who don't know (and...
06.03.2022
Episode 5: IDH Inhibitors in AML: not so AGILE
In this episode, Bernie Marini and Anthony Perissinotti chat with special guest Charles Foucar, MD, a hematology specialist and expert in the field. We discuss the controversial FDA approval of ivosidenib in combination with azacitidine in newly diagnosed IDH1+ AML,...
05.27.2022
Episode 4: All Aboard the Oncology StewardSHIP
In this episode, Bernie Marini and Anthony Perissinotti are joined by two special guest hematology experts - Lydia Benitez, PharmD, BCOP, and Madeleine Ochs, PharmD, BCOP. Maddy and Lydia help us dive into the topic of Oncology Stewardship, including how...
04.22.2022
Episode 3.2: Ranting About Rituximab in Acute Lymphoblastic Leukemia
In part two of this two-part episode, Bernie Marini and Anthony Perissinotti discuss the use of rituximab in acute lymphoblastic leukemia (ALL), based on the recent publication of the UKALL14 study (Marks, et al. Lancet Haematol, 2022): https://pubmed.ncbi.nlm.nih.gov/35358441/. We also...
04.22.2022
Episode 3.1: History of Acute Lymphoblastic Leukemia Treatment and Building the BFM Backbone
In part one of a two-part episode, Bernie Marini and Anthony Perissinotti take a journey through the history of acute lymphoblastic leukemia treatment throughout the decades and explain how we got to our current standard of care treatment of ALL...
03.18.2022
Episode 2: We Don't Talk About Rylaze
Bernie Marini and Anthony Perissinotti discuss asparaginase, the data (or lack thereof) behind the FDA approval of Rylaze (Erwinia asparaginase), and concerning trends regarding switches between asparaginase products in clinical practice!
03.11.2022
Episode 1: Surrogate Endpoints in AML
Bernie Marini and Anthony Perissinotti discuss the following paper on whether or not event-free survival (EFS) is an appropriate surrogate endpoint for overall survival (OS) in AML: Norsworthy KJ, et al. Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed...

What's WolverHeme Happy Hour about?

Download our free app to listen on your phone

WolverHeme Happy Hour episodes:

From Ancient Remedies to Modern Miracles: The Evolution of APL Treatment

Episode 24: Myeloma Madness with the Myeloma Man

Anthony and Bernie get rich on no-larabine! An ASH 2023 ALL discussion

LymphOMG: Pouring Over Lymphoma Abstracts from ASH

AMLchemy at ASH: Brewing Success with Menin Magic, MRD Mysteries, and Aza/Ven Alchemy

ASH Pregaming - Myeloma Madness with Manni and Papa Heme

AML Maintenance Part 2: a metaMORPHOsis?

AML Maintenance Part 1: Set Your QUAZARs to Stun

Episode 17: The Hemophilia Eras Tour

Common Sense Oncology: Outcomes That Matter

All too well: the reality of leukemia treatment

Episode 14: A Quantum Leap in AML Treatment? Dissecting Quizartinib Data with Dr. Dale Bixby

Episode 13: You get blinatumomab! You get blinatumomab!

Episode 12: Tinder for T Cells - Bispecifics in DLBCL

Episode 11: "Olu the Drunk Snowman" - IDH inhibitors in R/R AML with Dr. Jill Lykon

Episode 10: ASH Recap Part 2 - Papa Heme + WolverHeme

Episode 9: ASH Recap Part 1 - Dauno-Double Trouble

Episode 8: Pulling the Goalie on FLT3 Inhibitor Use in AML - A Discussion with Dr. Dale Bixby

Episode (3+)7: Straight Outta Roswell - OG AML Data

Episode 6: Dr. StrangeDrug or: How I Learned to Stop Worrying and Love the Asparaginase

Episode 5: IDH Inhibitors in AML: not so AGILE

Episode 4: All Aboard the Oncology StewardSHIP

Episode 3.2: Ranting About Rituximab in Acute Lymphoblastic Leukemia

Episode 3.1: History of Acute Lymphoblastic Leukemia Treatment and Building the BFM Backbone

Episode 2: We Don't Talk About Rylaze

Episode 1: Surrogate Endpoints in AML